Back to discover
Disease

Exanthema

Active therapeutic pipelineEmerging researchSteady momentum
5
Publications
1
Clinical trials
3
Related conditions
1
Related treatments
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways.

Research2024-07-01Clinical cancer research : an official journal of the American Association for Cancer Research

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.

Research2021-09-01The New England journal of medicine

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

Research2019-05-31The New England journal of medicine

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Research2018-02-08The New England journal of medicine

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial with recent milestones.
Major developments

Research-associated treatments

Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.

Clinical trials

1 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
1
All trials
1
Active
0
Late-stage
0
Completed

Research activity

5 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20182024
Most influential

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

The New England journal of medicine · 2019 · 1,013 cites

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

The New England journal of medicine · 2018 · 945 cites

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.

The New England journal of medicine · 2021 · 685 cites

Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2024 · 22 cites
Recent publications

Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2024 · 22 cites

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.

The New England journal of medicine · 2021 · 685 cites

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

The New England journal of medicine · 2019 · 1,013 cites

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

The New England journal of medicine · 2018 · 945 cites
Major themes5
  • Cytokines1
  • Exanthema1
  • Immune Checkpoint Inhibitors1
  • Neoplasms1
  • Skin Diseases1
Leading journals3
  • The New England journal of medicine3
  • Clinical cancer research : an official journal of the American Association for Cancer Research1
  • The British journal of dermatology1
Leading researchers8
  • Chowdhury S2
  • Uemura H2
  • Yu MK2
  • Abdullah SE1
  • Agarwal N1
  • Bang A1
  • Baurain JF1
  • Berdyshev E1
Affiliations (unnormalised)6
  • Chelsea and Westminster Hospital NHS Foundation Trust1
  • Department of Pathology and Laboratory Medicine1
  • From BC Cancer and Vancouver Prostate Centre1
  • From Mount Vernon Cancer Centre1
  • From the Massachusetts General Hospital Cancer Center and Harvard Medical School1
  • Ludwig Collaborative and Swim Across America Laboratory1

Related conditions

3 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Exanthema refers to diseases in which a skin eruption or rash is a prominent feature. In classic usage, it also encompassed a group of numbered childhood rash illnesses, of which only a few names remain in current terminology. The term is therefore broad and descriptive rather than a single specific disease entity.

Causes

The supplied grounding does not support a single cause for exanthema as a disease category. The literature provided only indicates that skin eruptions can occur as cutaneous adverse events during immune checkpoint inhibitor therapy, but it does not establish this as the cause of exanthema in general.

Pathophysiology

The grounding does not provide a disease-specific biological mechanism for exanthema. The review abstract does note that immune checkpoint inhibitors can trigger cutaneous immune-related adverse events, including maculopapular eruptions and other inflammatory dermatoses, but this is a treatment-associated mechanism rather than a general pathophysiology for exanthema.

Risk factors

The supplied material does not identify general risk factors for exanthema. It only indicates that exposure to immune checkpoint inhibitors is associated with cutaneous toxicities that may present as rash.

Current standard of care

No standard treatment for exanthema is supported by the supplied grounding. The review abstract indicates that cutaneous immune checkpoint inhibitor toxicities are often managed without stopping immunotherapy completely, but it does not provide a general treatment standard for exanthema itself.

AI-generated summary grounded in MeSH and 1 peer-reviewed source. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.

Identifiers
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.